Find in Library
Search millions of books, articles, and more
Indexed Open Access Databases
Seroprevalence of Herpes Simplex virus types 1 and 2 and their association with CD4 count among HIV-positive patients
oleh: Irna Sufiawati, Sunardhi Widyaputra, Tony S. Djajakusumah
| Format: | Article |
|---|---|
| Diterbitkan: | Universitas Airlangga 2012-06-01 |
Deskripsi
<p><span style="font-family: TribuneBold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Background: </strong><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>Herpes simplex virus (HSV) is a common cause of viral opportunistic infections among HIV-positive patients. </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>Frequent, more severe and prolonged episodes of recurrent HSV infection can be a source of significant morbidity and mortality </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>among HIV-positive patients with advanced immunosuppression, reflected by low CD4 count. However, conflicting results have also </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>been reported. </em><span style="font-family: TribuneBold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Purpose: </strong><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>The aim of this study was to investigate the seroprevalence of HSV type 1 (HSV-1) and type 2 (HSV-2) in </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>HIV-positive patients compare with the rate in HIV-negative patients, and to evaluate their association with CD4 count. </em><span style="font-family: TribuneBold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Methods: </strong><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>A cross sectional study was conducted among 145 subjects consisting of 80 HIV-positive and 65 HIV-negative patients attending the </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>top referral hospital in Bandung, West Java, Indonesia. The serum obtained was assayed for the presence of HSV-1 and HSV-2 IgG </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>antibodies using ELISA kits. Data were analyzed using a Chi-square test, t-tests and analysis of variance (ANOVA). </em><span style="font-family: TribuneBold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Results: </strong><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>There </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>were no significant differences in HSV-1 seroprevalence between HIV-positive patients (71%) and HIV-negative patients (66%). HSV-</em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>2 seroprevalence was significantly higher in HIV-positive patients (30%) than HIV-negative patients (5%). The titers of HSV-1 IgG </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>antibodies in HIV-positive patients (mean 24.63 ± 19.06 IDU) were significantly lower than those of HIV-negative patients (mean 44.62 </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>± 33.22 IDU). In contrast, HSV-2 IgG antibody titers in HIV-positive patients (mean 13.31 ± 20.28 IDU) were significantly higher than </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>HIV-negative patients (mean 4.42 ± 10.99 IDU). There was no significant correlation between HSV-1 and HSV-2 seropositivity and </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>CD4 count among HIV-positive patients. However, most of HSV-2 seropositive patients had CD4 count < 200 cells/mm</em><span style="font-family: TribuneItalic; font-size: 7pt; color: #231f20; font-style: normal; font-variant: normal;"><em>3</em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>. </em><span style="font-family: TribuneBold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Conclusion: </strong><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>Seroprevalence of HSV-1 and HSV-2 among HIV-positive patients was high with no correlation with CD4 count.</em></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p><span style="font-family: TribuneBold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneBold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneBold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneBold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 7pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneBold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em><span style="font-family: TribuneBold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Latar belakang: </strong><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>Herpes simplex virus (HSV) adalah penyebab infeksi virus oportunistik yang paling umum pada pasien HIVpositif. Infeksi HSV rekuren yang sering terjadi, lebih berat, dan episode yang berkepanjangan dapat menjadi penyebab morbiditas </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>dan mortalitas yang signifikan pada pasien HIV-positif dengan imunosupresi lanjut, ditandai dengan jumlah CD4 yang rendah. </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>Namun, hasil yang bertentangan juga telah dilaporkan. </em><span style="font-family: TribuneBold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Tujuan: </strong><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>Penelitian ini bertujuan untuk mengetahui seroprevalensi HSV tipe 1 </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>(HSV-1) dan tipe 2 (HSV-2) pada pasien HIV-positif dibandingkan dengan pasien HIV-negatif, dan untuk mengevaluasi hubungannya </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>dengan jumlah CD4. </em><span style="font-family: TribuneBold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Metode: </strong><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>Penelitian potong lintang ini dilakukan pada 145 subjek yang terdiri dari 80 pasien HIV-positif dan 65 </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>pasien HIV-negatif yang berkunjung ke rumah sakit pusat rujukan di Bandung, Jawa Barat, Indonesia. Antibodi IgG HSV-1 dan HSV-</em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>2 di dalam serum diperiksa dengan menggunakan ELISA. Data dianalisis dengan uji Chi-square, t-test dan ANOVA, nilai p < 0.05 </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>dianggap signifikan secara statistik. </em><span style="font-family: TribuneBold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Hasil: </strong><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>Seroprevalensi antibodi IgG HSV-1 pada pasien HIV-positif (71%) tidak berbeda secara </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>signifikan dengan pasien HIV-negatif (66%). Namun, seroprevalensi HSV-2 secara signifikan lebih tinggi pada pasien HIV-positif </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>(30%) dibandingkan dengan pasien HIV-negatif (5%). Titer antibodi IgG HSV-1 pada pasien HIV-positif (mean 24.63 ± 19.06 IDU) </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>secara signifikan lebih rendah dibandingkan pasien HV-negatif (mean 44.62 ± 33.22 IDU). Sedangkan, titer antibodi IgG HSV-2 pada </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>pasien HIV-positif (mean 13.31 ± 20.28 IDU) secara signifikan lebih tinggi dibandingkan pasien HIV-negatif (mean 4.42 ± 10.99 </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>IDU). Tidak ada hubungan yang signifikan antara seropositivitas HSV-1 dan -2 dengan jumlah CD4. Namun, sebagian besar pasien</em></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span> <span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>seropositif HSV-2 memiliki jumlah CD4 < 200 sel/mm</em><span style="font-family: TribuneItalic; font-size: 7pt; color: #231f20; font-style: normal; font-variant: normal;"><em>3</em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>. </em><span style="font-family: TribuneBold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Kesimpulan: </strong><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>Seroprevalensi HSV-1 dan HSV-2 pada pasien HIV-positif </em><span style="font-family: TribuneItalic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>adalah tinggi, tetapi tidak berkorelasi dengan jumlah CD4.</em></span></span></span></span></span></span><br /></em></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>